Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115154 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
A Phase 4 study of Keratosis, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
- 18
- Study locations
NCT00115154: Completed Phase 4 study of Keratosis, sponsored by Graceway Pharmaceuticals.
NCT00115154 is a Phase 4 study of Keratosis that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 270 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115154, a Phase 4 study of Keratosis, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.
Conditions Studied
Interventions
- DRUG Aldara (imiquimod) cream, 5%
Study Locations (18)
Georgia
- - Atlanta
- - Newnan
New York
- - New York
- - Rochester
Texas
- - Dallas
- - Houston
Arizona
- - Tucson
California
- - Vista
Illinois
- - Buffalo Grove
Indiana
- - Evansville
New Jersey
- - Riverside Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
What the finished NCT00115154 record still lists
NCT00115154 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Keratosis appearing as the primary indexed condition, and to 1 intervention - of which Aldara (imiquimod) cream, 5% is the first listed.
NCT00115154 lists 18 locations in 15 states (Georgia, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT00115154 about?
NCT00115154 is a clinical study titled "Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands". The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.
What is the current status of trial NCT00115154?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2005-05. Estimated completion is 2006-09.
What conditions does trial NCT00115154 study?
This clinical trial studies the following conditions: Keratosis.
What interventions are being tested in trial NCT00115154?
The interventions under investigation include: Aldara (imiquimod) cream, 5% (DRUG).
Who is sponsoring clinical trial NCT00115154?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115154 being conducted?
This trial has 18 study locations across Arizona, California, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00115154's enrollment target sits among peer trials
270 318th of 2000 higher than 1,682 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia